Photo of Arndt Vogel from journalonko.de
Jun 27, 2024, 08:31
Arndt Vogel: Phase I study of the PKMYT1 inhibitor lunresertib in combination with FOLFIRI
Arndt Vogel shared on X:
“Phase I study of the PKMYT1 inhibitor lunresertib in combination with FOLFIRI in advanced GI cancers at ESMOGI24
- MINOTAUR study
- Interesting MOA, for 20% of pts w/ CCCN1 amp or mFBXW7 >synthetically lethality
- acceptable safety, “promising” efficacy”
Source: Arndt Vogel/X
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer.
He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.